Skip to content

Executive Director, Payer Strategy and Engagement (Tumor HI Program)

RezolutebioRedwood City

First seen Jun 2 · open 171 days · posted onceNo pay listed

HirQ verdict

50/100 · Fair. Based on age, reposts, pay, the company's hiring and ghost signals.

Low ghost risk
True age
171 days
Reposts
Posted once

See the evidence behind this score.

Pro shows each part of the score, the reasons, the pay percentile and the listing history.

HirQ's ghost-risk estimate and company labels are automated opinions based on what we observe on employers' public job boards: how long a listing has been open, whether it was re-listed, wording in the description, and how often roles on that board close. They are not statements about an employer's intent, and a high-risk listing can still be a real opening. Figures are as of the date shown. How we measure

At a glance

Pay
No pay listed
Level
Director
Type
Full Time
Team
Market Access & Policy
Work setup
On-site

“Redwood City”

Rezolutebio hiring

Company page
SlowingHiring48· WeakBiotech & Pharma
Open roles
20
New in 30 days
6
Closed in 30 days
3
Hiring trend, 13 weeksPro
Follow-through: ••%Pro

About the role

From Rezolutebio's careers page, checked Nov 20

Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation, collaboration, and integrity.
Rezolute’s lead investigational therapy, RZ358 (ersodetug), is a fully human monoclonal antibody in late-stage clinical development for the treatment of hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI). As Rezolute expands its medical and scientific focus into tumor-related hyperinsulinism (tumor HI), most commonly related to pancreatic neuroendocrine tumors (insulinomas) or paraneoplastic hypoglycemia (NICTH), the company is committed to advancing novel therapeutic strategies that address this rare and complex form of hypoglycemia associated with insulin-secreting tumors and related neuro-oncology disorders.

Apply on Rezolutebio's siteOpens Rezolutebio's own application page.

Similar jobs

Same role or field, nearby or remote, ranked by HirQ score.

More at Rezolutebio

All roles

Keep exploring

Executive Director, Payer Strategy and Engagement (Tumor HI Program)

No pay listed · HirQ 50

Apply